This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEGAH149_L.jpg
It said the updated analysis was based on 8,000 trial participants. Pfizer said in a previous analysis that 3.7% of 6,000 volunteers had experienced fatigue.
Pfizer also added that there was a second adverse event with a frequency of at least 2% in the trial. The U.S. drugmaker said 2% of participants experienced headaches after the second shot.
